CREST-E

Creatine Safety, Tolerability, & Efficacy in Huntington’s Disease

The Huntington Study Group (HSG), in a partnership between Massachusetts General Hospital (MGH) and the University of Rochester, is conducting a clinical trial to study the effects of creatine monohydrate in persons 18 years of age and older who have clinical features of Huntington’s Disease (HD). CREST-E is designed to measure the effects of creatine monohydrate on the progression of HD in comparison to placebo (looks like study drug but has no active ingredient). CREST-E is designed to determine if creatinine monohydrate is safe and tolerable and to examine its effects on the body.

Approximately 44 research centers around the world will enroll up to 650 participants for a 37-month follow-up period. Enrollment began in Fall 2009. This study is sponsored by the National Center for Complementary and Alternative Medicine (NCCAM) and the U.S. Food and Drug Administration (FDA) Orphan Products division.

Please see the CREST-E Participating Site List. Please check back often. New sites will be added to this list as they secure the approval required to enroll study participants. Thank you.


Home Clinical Research Clinical Trials/Observational Studies in Progress 2CARE COHORT CREST-E DIMOND HART HORIZON PHAROS PREDICT-HD PREQUEL RESPOND-HD Completed Clinical Trials HSG Research Sites Request for Proposals About Us HSG Overview HSG Executive Committee HSG Working Groups Standing HSG Committees Becoming an HSG Research Site Education Resources Login FAQ's Clinical Care UHDRS Links Publications News & Events Events & Upcoming Meetings PSG/HSG Symposium Huntington Disease Clinical Research Symposium Giving Contact Us	Creatine Safety, Tolerability, & Efficacy in Huntington’s Disease The Huntington Study Group (HSG), in a partnership between Massachusetts General Hospital (MGH) and the University of Rochester, is conducting a clinical trial to study the effects of creatine monohydrate in persons 18 years of age and older who have clinical features of Huntington’s Disease (HD). CREST-E is designed to measure the effects of creatine monohydrate on the progression of HD in comparison to placebo (looks like study drug but has no active ingredient). CREST-E is designed to determine if creatinine monohydrate is safe and tolerable and to examine its effects on the body. Approximately 44 research centers around the world will enroll up to 650 participants for a 37-month follow-up period. Enrollment began in Fall 2009. This study is sponsored by the National Center for Complementary and Alternative Medicine (NCCAM) and the U.S. Food and Drug Administration (FDA) Orphan Products division. Please see the CREST-E Participating Site List. Please check back often. New sites will be added to this list as they secure the approval required to enroll study participants. Thank you. Related Documents: CREST-E Participating Site List CREST-E Brochure Related Links: Clinical Trials.gov last updated: March 2010